Bisphosphonate-induced osteonecrosis: dental considerations.
Gross
Howard B
HB
Department of Periodontology, School of Dental Medicine, University of Pennsylvania, USA.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D024042:Collagen Type I / Q000097:blood; D000075202:Contraindications; D003646:Debridement; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D009910:Oral Hygiene; D019647:Oral Surgical Procedures; D010020:Osteonecrosis / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D010455:Peptides / Q000097:blood
D000900:Anti-Bacterial Agents; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide